Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

ImmunityBio reports breakthrough survival in lung cancer with "Immunotherapy 2.0"

ImmunityBio (NASDAQ:IBRX) announced positive results Tuesday from its ANKTIVA® clinical program, signaling a potential paradigm shift in the treatment of advanced non-small cell lung cancer (NSCLC) for patients who have exhausted standard-of-care options.

Leia mais: ImmunityBio reports breakthrough survival in lung cancer with "Immunotherapy 2.0"
Grafa
Health

BriaCell reports sustained lung tumor clearance in early immunotherapy trial

BriaCell Therapeutics Corp. (NASDAQ:BCTX) announced Tuesday that the first patient in its Bria-OTS trial achieved an 11-month sustained complete resolution of a lung metastasis, providing a significant early validation for the company’s personalized "off-the-shelf" immunotherapy platform.

Leia mais: BriaCell reports sustained lung tumor clearance in early immunotherapy trial
Grafa
Health

Fortress Biotech shares jump on FDA approval of ZYCUBO for Menkes disease

Fortress Biotech Inc. (Nasdaq: FBIO) and its majority-owned subsidiary, Cyprium Therapeutics, secured a historic regulatory victory Tuesday as the U.S. Food and Drug Administration approved ZYCUBO® (copper histidinate) as the first-ever treatment for Menkes disease.

Leia mais: Fortress Biotech shares jump on FDA approval of ZYCUBO for Menkes disease
Grafa
Health

Cardiol Therapeutics hits halfway mark in pivotal heart inflammation trial

Cardiol Therapeutics (NASDAQ:CRDL) announced Tuesday that it has surpassed 50% patient enrollment in its pivotal Phase III MAVERIC trial, a major step toward bringing the first non-immunosuppressive oral therapy to patients suffering from recurrent pericarditis.

Leia mais: Cardiol Therapeutics hits halfway mark in pivotal heart inflammation trial